Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

Inclusion Criteria:

• Age ≥ 18 years

• Prior diagnosis of a glioma treated with chemotherapy and/or radiation with stabledisease based on Response Assessment in Neuro-Oncology (RANO) criteria

• Must have IDH-mutant OR MGMT-methylated glioma

• NOTE: Patients with any radiographic evidence of residual disease areeligible

• Eastern Cooperative Oncology Group (ECOG) of 0, 1, or 2, and Karnofsky performancestatus >= 50

• Hemoglobin ≥ 9.0 g/dL (≤ 15 days prior to registration)

• Absolute neutrophil count (ANC) ≥ 1500/mm^3 (≤ 15 days prior to registration)

• Platelet count ≥ 100,000/mm^3 (without transfusion ≤ 7 days preceding labassessment) (≤ 15 days prior to registration)

• Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x upper limitof normal (ULN) (or ≤ 5 x ULN for patients with liver involvement) (≤ 15 days priorto registration)

• Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula (≤ 15days prior to registration)

• Average corrected QT interval (QTc) ≤ 450 ms on triplicate 12 lead electrocardiogram (ECG) ≤ 29 days prior to registration

• NOTE: QTc intervals will be corrected using Fridericia's formula (Fridericia

• Negative serum pregnancy test is required for persons of childbearing potential ≤ 8days prior to registration

• Presence of an implanted cranial CSF access device, such as Ommaya reservoir orventriculoperitoneal shunt

• Willingness to provide blood and CSF samples for research

• Co-enrollment on the neuro-oncology biorepository [institutional review board (IRB) 12-003458] for collection of research blood and CSF samples

• Provide written informed consent

• Willingness to return to Mayo Clinic for follow-up

Exclusion Criteria:

• Any of the following because this study involves an agent that has known genotoxic,mutagenic and teratogenic effects:

• Pregnant persons

• Nursing persons

• Persons of childbearing potential and persons able to father a child who areunwilling to employ adequate contraception

• Patients who are not appropriate medical candidates due to current or past medicalhistory or uncontrolled concurrent illness which limits safety of or compliance tostudy proceedings

• Participants who are unable to swallow tablets or who are at risk for impairedabsorption of oral medication

• NOTE: This includes but not limited to, refractory vomiting, gastricresection/bypass, or duodenal/jejunal resection

• Patients with known hypersensitivity or allergy to all of the study drugs on theprotocol (known hypersensitivity or allergy to one drug does not precludeparticipation in this protocol)

• Inability to undergo MRI scans